Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC

Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC

Detalles Bibliográficos
Main Authors:	Heymach, J, Hanrahan, E, Mann, H, Langmuir, P, Natale, R, Johnson, B, Herbst, R, Ryan, A
Formato:	Journal article
Publicado:	2008

Títulos similares

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
por: Hanrahan, E, et al.
Publicado: (2009)

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
por: Hanrahan, E, et al.
Publicado: (2010)

Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
por: Siemann, D, et al.
Publicado: (2009)

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
por: Wells, SA, et al.
Publicado: (2012)

Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study
por: Christina L. Addison, et al.
Publicado: (2015-06-01)

Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time Reply
por: Jr, W, et al.
Publicado: (2012)

Vandetanib for Advanced Non-small Cell Lung Cancer: A Meta-analysis
por: Ling TAO, et al.
Publicado: (2012-03-01)

Selective use of vandetanib in the treatment of thyroid cancer
por: Fallahi P, et al.
Publicado: (2015-07-01)

Biophysical and computational characterization of vandetanib–lysozyme interaction
por: Kabir, Md Zahirul, et al.
Publicado: (2018)

Investigating the effect of vandetanib and celecoxib combination on angiogenesis
por: Abdul Qadir, MPhil, et al.
Publicado: (2023-10-01)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Nils Degrauwe, et al.
Publicado: (2012-06-01)

Dermoscopic findings of perifollicular pigmentation associated with vandetanib
por: Jade Cury-Martins, et al.
Publicado: (2018-10-01)

Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
por: Mijin Kim, et al.
Publicado: (2020-09-01)

Vandetanib Treatment in Refractory Advanced Lung Adenocarcinoma Patients:  Five Cases and Review of Literature
por: Lili GUO, et al.
Publicado: (2012-02-01)

Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
por: Wachsberger, P, et al.
Publicado: (2009)

Inhibitory effect of luteolin on the metabolism of vandetanib in vivo and in vitro
por: Yuxin Shen, et al.
Publicado: (2025-03-01)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Hari Deshpande, et al.
Publicado: (2011-01-01)

Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.
por: Alferez, D, et al.
Publicado: (2010)

Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
por: Choi, S, et al.
Publicado: (2008)

Vandetanib induced phototoxic reaction progressed to toxic epidermal necrolysis
por: Busra Demirbag Gul, et al.
Publicado: (2022-02-01)

The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
por: Cesca, M, et al.
Publicado: (2009)

Prolonged Progression-Free Survival with Partial Disease Regression in Advanced Metastatic Medullary Thyroid Carcinoma Treated with Vandetanib
por: Sravanthi Sanivarapu, MD, et al.
Publicado: (2018-09-01)

Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular Carcinoma
por: Hideki Iwamoto, et al.
Publicado: (2011-03-01)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
por: Fallahi P, et al.
Publicado: (2019-08-01)

A secondary RET mutation in the activation loop conferring resistance to vandetanib
por: Takashi Nakaoku, et al.
Publicado: (2018-02-01)

Vandetanib as a prospective anti-inflammatory and anti-contractile agent in asthma
por: Xiaoyue Zeng, et al.
Publicado: (2024-05-01)

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD
por: Miltiadis K. Tsilimbaris, et al.
Publicado: (2016-01-01)

Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients
por: Luigi Della Gravara, et al.
Publicado: (2021-06-01)

Editorial: Emerging Biomarkers for NSCLC: Recent Advances in Diagnosis and Therapy
por: Umberto Malapelle, et al.
Publicado: (2021-05-01)

Vascular Endothelial Growth Factor Concentration as a Predictive Marker: Ready for Primetime? Response
por: Hanrahan, E, et al.
Publicado: (2010)

The effect of baseline versus early glucocorticoid use on immune checkpoint inhibitor efficacy in patients with advanced NSCLC
por: Yifan Wang, et al.
Publicado: (2025-01-01)

Efficacy of vandetanib in the treatment of medullary thyroid cancer: literature review and case report
por: А. М. Mudunov, et al.
Publicado: (2019-10-01)

The Effects of Vandetanib on Paclitaxel Tumor Distribution and Antitumor Activity in a Xenograft Model of Human Ovarian Carcinoma
por: Marta Cesca, et al.
Publicado: (2009-11-01)

Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.
por: Wei Tian, et al.
Publicado: (2013-01-01)

Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients
por: Lingzhi Hong, et al.
Publicado: (2024-10-01)

Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer
por: Ecem Bostan, et al.
Publicado: (2022-09-01)

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
por: Jaclyn Flanigan, et al.
Publicado: (2010-08-01)

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
por: Brave, SR, et al.
Publicado: (2011)

Immunotherapeutic Advances for NSCLC
por: Massafra M, et al.
Publicado: (2021-10-01)

Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis
por: Pierpaolo Trimboli, et al.
Publicado: (2018-05-01)